New antibody therapy shows promise for Hard-to-Treat multiple myeloma

NCT ID NCT03145181

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-stage study tests a new drug called teclistamab in people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find a safe dose and check for side effects. About 300 participants will receive the drug to see how well it works and how the body handles it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Locations

CHRU Tours Hopital Bretonneau

Tours, 37044, France
City of Hope

Duarte, California, 91010, United States
Clinica Univ. de Navarra

Pamplona, 31008, Spain
Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
Haematology Centre, R 51

Stockholm, SE-141 86, Sweden
Hosp Clinic de Barcelona

Barcelona, 08036, Spain
Hosp Clinico Univ de Salamanca

Salamanca, 37007, Spain
Hosp. Univ. Germans Trias I Pujol

Badalona, 08916, Spain
Hospices Civils de Lyon HCL

Lyon, 69002, France
Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects

New York, New York, 10029, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
VU Medisch Centrum

Amsterdam, 1081 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.